Aerivio Spiromax

1 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ANNEX I 

 

SUMMARY OF PRODUCT CHARACTERISTICS 

Me
dic

ina
l p

ro
du

ct 
no

 lo
ng

er
 au

th
or

ise
d



2 

1. NAME OF THE MEDICINAL PRODUCT 

 

Aerivio Spiromax 50 micrograms/500 micrograms inhalation powder 

 

 

2. QUALITATIVE AND QUANTITATIVE COMPOSITION 

 

Each metered dose contains 50 micrograms of salmeterol (as salmeterol xinafoate) and 500 micrograms of 

fluticasone propionate. 

 

Each delivered dose (the dose from the mouthpiece) contains 45 micrograms of salmeterol (as salmeterol 

xinafoate) and 465 micrograms of fluticasone propionate. 

 

 
Excipient(s) with known effect: 

Each dose contains approximately 10 milligrams of lactose (as monohydrate). 

 

For the full list of excipients, see section 6.1. 

 

 

3. PHARMACEUTICAL FORM 

 

Inhalation powder. 

 

White powder. 

 

White inhaler with a semi-transparent yellow mouthpiece cover.  

 

 

4. CLINICAL PARTICULARS 

 

4.1 Therapeutic indications 

 

Aerivio Spiromax is indicated for use in adults aged 18 years and older only. 

 

Asthma 

Aerivio Spiromax is indicated for the regular treatment of patients with severe asthma where use of a 

combination product (inhaled corticosteroid and long-acting β2 agonist) is appropriate: 

 

- patients not adequately controlled on a lower strength corticosteroid combination product  

or 

- patients already controlled on a high dose inhaled corticosteroid and long-acting β2 agonist. 

 

 

Chronic Obstructive Pulmonary Disease (COPD) 

Aerivio Spiromax is indicated for the symptomatic treatment of patients with COPD, with a FEV1 <60% 

predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant 

symptoms despite regular bronchodilator therapy. 

 

4.2 Posology and method of administration 

 

Aerivio Spiromax is indicated in adults 18 years of age and older only. 

Aerivio Spiromax is not indicated for use in children, 12 years of age and younger or adolescents, 13 to 17 

years of age. 

 

 

Me
dic

ina
l p

ro
du

ct 
no

 lo
ng

er
 au

th
or

ise
d



3 

 

Posology 

 

Route of administration: Inhalation use 

 

Patients should be made aware that Aerivio Spiromax must be used daily for optimum benefit, even when 

asymptomatic. 

 

Patients should be regularly reassessed by a doctor, so that the strength of the salmeterol/fluticasone 

propionate inhaler they are receiving remains optimal and is only changed on medical advice. The dose 

should be titrated to the lowest dose at which effective control of symptoms is maintained. Aerivio 

Spiromax is not available on the market at strengths lower than 50/500 microgram. When it is appropriate to 

titrate down to a lower strength not available for Aerivio Spiromax, a change to an alternative fixed-dose 

combination of salmeterol and fluticasone propionate containing a lower dose of the inhaled corticosteroid is 

required. 

 

Patients should be given a strength of salmeterol/fluticasone propionate inhaler containing the appropriate 

fluticasone propionate dosage for the severity of their disease.   Aerivio Spiromax is only appropriate for use 

in the treatment of patients with severe asthma.  If an individual patient should require dosages outside the 

recommended regimen, appropriate doses of β2 agonist and/or corticosteroid should be prescribed 

 

Recommended doses: 

 

Asthma 

Adults aged 18 years and older. 

 

One inhalation of 50 micrograms salmeterol and 500 micrograms fluticasone propionate twice daily. 

 

Once control of asthma is attained treatment should be reviewed and consideration given as to whether 

patients should be stepped down to an alternative fixed-dose combination of salmeterol and fluticasone 

propionate containing a lower dose of the inhaled corticosteroid and then ultimately to an inhaled 

corticosteroid alone. Regular review of patients as treatment is stepped down is important. 

 

A clear benefit has not been shown as compared with inhaled fluticasone propionate alone used as initial 

maintenance therapy when one or two of the criteria of severity are missing. In general inhaled 

corticosteroids remain the first line treatment for most patients.  

 

Aerivio Spiromax is for the treatment of patients with severe asthma only. It should not be used for the 

treatment of patients with mild or moderate asthma or for the initiation of treatment for patients with severe 

asthma unless the requirement for such a high dose of the corticosteroid together with a long-acting β2 
agonist has been established previously.  

 

Aerivio Spiromax is not intended as the treatment of asthma when a fixed-dose combination of salmeterol 

and fluticasone propionate is required for the first time.  Patients should commence treatment with a fixed-

dose combination containing a lower dose of the corticosteroid component and will then be titrated up in 

respect of the corticosteroid dose until control of asthma is achieved.  Once control of asthma is achieved 

patients should be reviewed regularly and the dose of inhaled corticosteroid titrated downwards as 

appropriate to maintain disease control. 

 

It is recommended to establish the appropriate dosage of inhaled corticosteroid before any fixed-dose 

combination can be used in patients with severe asthma. 

 

Me
dic

ina
l p

ro
du

ct 
no

 lo
ng

er
 au

th
or

ise
d



4 

Paediatric population 

Aerivio Spiromax is not recommended for use in either children aged 12 years of age and younger or in 

adolescents aged 13 to 17 years. The safety and efficacy of Aerivio Spiromax in children and adolescents 

aged less than 18 years of age has not been established.  

No data are available. 

 

COPD 

One inhalation of 50 micrograms salmeterol and 500 micrograms fluticasone propionate twice daily. 

 

Special patient groups 

There is no need to adjust the dose in elderly patients or in those with renal impairment.  

 

There are no data available on the use of Aerivio Spiromax in patients with hepatic impairment. 

 

Method of administration/Instructions for use  

 

The Spiromax device is a breath actuated, inspiratory flow-driven inhaler, which means that the active 

substances are delivered into the airways when the patient inhales through the mouthpiece. Patients with 

severe asthma and COPD were shown to be able to generate sufficient inspiratory flow rate when they 

breathed in forcefully through the Spiromax device to enable the delivery of the required therapeutic dose to 

the lungs (see also section 5.1 – last five paragraphs)  

 

Required training 

Aerivio Spiromax should be used correctly in order to achieve effective treatment. As such, the patients 

should be advised to read the patient information leaflet carefully and follow the instructions for use as 

detailed in the leaflet. All patients should be provided with training by the prescribing Health Care 

Professional on how to use Aerivio Spiromax. This is to ensure that they understand how to use the inhaler 

correctly, and so that they understand the need to breathe in forcefully when inhaling to obtain the required 

dose.  It is important to inhale forcefully to ensure optimal dosing. 

 

The use of Aerivio Spiromax follows three simple steps: open, breathe and close which are outlined below. 

 

Open: Hold the Spiromax with the mouthpiece cover at the bottom and open the mouthpiece cover by 

folding it down until it is fully opened when one click is heard. 

 

Breathe: Breathe out gently (as far as is comfortable). Do not breathe through your inhaler. Place the 

mouthpiece between the teeth with the lips closed around the mouthpiece, do not bite the mouthpiece of the 

inhaler. Breathe in forcefully and deeply through the mouthpiece. Remove the Spiromax device from the 

mouth and hold the breath for 10 seconds or as long as comfortable for the patients. 

 

Close: Breathe out gently and close the mouthpiece cover. 

 

Patients should not block the air vents at any time, or breathe out through the Spiromax device when they are 

preparing the “Breathe” step. Patients are not required to shake the inhaler prior to use.  

 

Patients should also be advised to rinse their mouth with water and spit the water out, and/or brush their teeth 

after inhaling (see section 4.4) 

 

Patients may notice a taste when using Aerivio Spiromax due to the lactose excipient. 

 

4.3 Contraindications 

 

Hypersensitivity to the active substances or to any of the excipients listed in section 6.1. 

 

Me
dic

ina
l p

ro
du

ct 
no

 lo
ng

er
 au

th
or

ise
d



5 

4.4 Special warnings and precautions for use 

 

Asthma 

Aerivio Spiromax is for use in patients with severe asthma only. It should not be used to treat acute asthma 

symptoms for which a fast- and short-acting bronchodilator is required. Patients should be advised to have 

their inhaler to be used for relief in an acute asthma attack available at all times. 

 

Patients should not be initiated on Aerivio Spiromax during an exacerbation, or if they have significantly 

worsening or acutely deteriorating asthma. 

 

Serious asthma-related adverse events and exacerbations may occur during treatment with Aerivio Spiromax. 

Patients should be asked to continue treatment but to seek medical advice if asthma symptoms remain 

uncontrolled or worsen after initiation on Aerivio Spiromax. 

 

Increased requirements for use of reliever medication (short-acting bronchodilators), or decreased response 

to reliever medication indicate deterioration of asthma control and patients should be reviewed by a 

physician. 

 

Sudden and progressive deterioration in control of asthma is potentially life-threatening and the patient 

should undergo urgent medical assessment. Consideration should be given to increasing corticosteroid 

therapy.  

 

Once asthma symptoms are controlled, consideration may be given to gradually reducing the dose of the 

inhaled corticosteroid and therefore a change to an alternative fixed-dose combination of salmeterol and 

fluticasone propionate containing a lower dose of the inhaled corticosteroid is required. Regular review of 

patients as treatment is stepped down is important. The lowest dose of inhaled corticosteroid should be used. 

 

COPD 

For patients with COPD experiencing exacerbations, treatment with systemic corticosteroids is typically 

indicated, therefore patients should be instructed to seek medical attention if symptoms deteriorate with 

Aerivio Spiromax. 

 

Cessation of therapy 

Treatment with Aerivio Spiromax should not be stopped abruptly in patients with asthma due to risk of 

exacerbation. Therapy should be down-titrated under physician supervision. For patients with COPD 

cessation of therapy may also be associated with symptomatic decompensation and should be supervised by 

a physician. 

 

Caution with special diseases 

Aerivio Spiromax should be administered with caution in patients with active or quiescent pulmonary 

tuberculosis and fungal, viral or other infections of the airway. Appropriate treatment should be promptly 

instituted, if indicated. 

 

Rarely, Aerivio Spiromax may cause cardiac arrhythmias e.g. supraventricular tachycardia, extrasystoles and 

atrial fibrillation, and a mild transient reduction in serum potassium at high therapeutic doses. Aerivio 

Spiromax should be used with caution in patients with severe cardiovascular disorders or heart rhythm 

abnormalities and in patients with diabetes mellitus, thyrotoxicosis, uncorrected hypokalaemia or patients 

predisposed to low levels of serum potassium. 

There have been very rare reports of increases in blood glucose levels (see section 4.8) and this should be 

considered when prescribing to patients with a history of diabetes mellitus. 

 

Parodoxical bronchospasm 

Paradoxical bronchospasm may occur with an immediate increase in wheezing and shortness of breath after 

dosing. Paradoxical bronchospasm responds to a rapid-acting bronchodilator and should be treated 

straightaway. Aerivio Spiromax should be discontinued immediately, the patient assessed and alternative 

therapy instituted if necessary. 

Me
dic

ina
l p

ro
du

ct 
no

 lo
ng

er
 au

th
or

ise
d



6 

 

 

βeta 2 adrenoreceptor agonists 

The pharmacological effects of β2 agonist treatment, such as tremor, palpitations and headache, have been 

reported, but tend to be transient and reduce with regular therapy. 

 

Systemic effects 

Systemic effects may occur with any inhaled corticosteroid, particularly at high doses prescribed for long 

periods. These effects are much less likely to occur than with oral corticosteroids. Possible systemic effects 

include Cushing’s syndrome, Cushingoid features, adrenal suppression, decrease in bone mineral density, 

cataract and glaucoma and more rarely, a range of psychological or behavioural effects including 

psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression (particularly in children) (see 

Paediatric population sub-heading below for information on the systemic effects of inhaled corticosteroids in 

children and adolescents). It is important, therefore, that the patient is reviewed regularly and the dose 

of inhaled corticosteroid is reduced to the lowest dose at which effective control of asthma is 

maintained. 

 

Visual disturbance 

Visual disturbance may be reported with systemic and topical corticosteroid use. If a patient presents with 

symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to 

an ophthalmologist for evaluation of possible causes which may include cataract, glaucoma or rare diseases 

such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical 

corticosteroids. 

 

Adrenal function 

Prolonged treatment of patients with high doses of inhaled corticosteroids may result in adrenal suppression 

and acute adrenal crisis. Very rare cases of adrenal suppression and acute adrenal crisis have also been 

described with doses of fluticasone propionate between 500 and less than 1000 micrograms. Situations, 

which could potentially trigger acute adrenal crisis include trauma, surgery, infection or any rapid reduction 

in dosage. Presenting symptoms are typically vague and may include anorexia, abdominal pain, weight loss, 

tiredness, headache, nausea, vomiting, hypotension, decreased level of consciousness, hypoglycaemia, and 

seizures. Additional systemic corticosteroid cover should be considered during periods of stress or elective 

surgery. 

 

The benefits of inhaled fluticasone propionate therapy should minimise the need for oral steroids, but 

patients transferring from oral steroids may remain at risk of impaired adrenal reserve for a considerable 

time. Therefore these patients should be treated with special care and adrenocortical function regularly 

monitored. Patients who have required high dose emergency corticosteroid therapy in the past may also be at 

risk. This possibility of residual impairment should always be borne in mind in emergency and elective 

situations likely to produce stress, and appropriate corticosteroid treatment must be considered. The extent of 

the adrenal impairment may require specialist advice before elective procedures. 

 

Interactions with other medicinal products 

Ritonavir can greatly increase the concentration of fluticasone propionate in plasma. Therefore, concomitant 

use should be avoided, unless the potential benefit to the patient outweighs the risk of systemic corticosteroid 

side effects. There is also an increased risk of systemic undesirable effects when combining fluticasone 

propionate with other potent CYP3A inhibitors (see section 4.5). 

 

Concomitant use of systemic ketoconazole significantly increases systemic exposure to salmeterol. This may 

lead to an increase in the incidence of systemic effects (e.g. prolongation in the QTc interval and 

palpitations). Concomitant treatment with ketoconazole or other potent CYP3A4 inhibitors should therefore 

be avoided unless the benefits outweigh the potentially increased risk of systemic undesirable effects of 

salmeterol treatment (see section 4.5). 

 

Me
dic

ina
l p

ro
du

ct 
no

 lo
ng

er
 au

th
or

ise
d



7 

Respiratory tract infections 

There was an increased reporting of lower respiratory tract infections (particularly pneumonia and 

bronchitis) in the TORCH study in patients with COPD receiving salmeterol/fluticasone propionate 

50/500 micrograms twice daily compared with placebo as well as in studies SCO40043 and SCO100250 

comparing a lower dose of salmeterol/fluticasone propionate 50/250 micrograms twice daily, (a dose not 

authorised for use in COPD) with salmeterol 50 micrograms twice daily only (see section 4.8 and section 

5.1). A similar incidence of pneumonia in the salmeterol/fluticasone propionate group was seen across all 

studies. In TORCH, older patients, patients with a lower body mass index (<25 kg/m
2
) and patients with very 

severe disease (FEV1<30% predicted) were at greatest risk of developing pneumonia regardless of treatment.  

 

Physicians should remain vigilant for the possible development of pneumonia and other lower respiratory 

tract infections in patients with COPD as the clinical features of such infections and exacerbation frequently 

overlap. If a patient with severe COPD has experienced pneumonia, treatment with Aerivio Spiromax should 

be re-evaluated. 

 

Pneumonia in patients with COPD 

An increase in the incidence of pneumonia, including pneumonia requiring hospitalisation, has been 

observed in patients with COPD receiving inhaled corticosteroids. There is some evidence of an increased 

risk of pneumonia with increasing steroid dose but this has not been demonstrated conclusively across all 

studies. 

 

There is no conclusive clinical evidence for intra-class differences in the magnitude of the pneumonia risk 

among inhaled corticosteroid products. 

 

Physicians should remain vigilant for the possible development of pneumonia in patients with COPD as the 

clinical features of such infections overlap with the symptoms of COPD exacerbations.  If a patient with 

severe COPD has experienced pneumonia, treatment with Aerivio Spiromax should be re-evaluated. 

 

Risk factors for pneumonia in patients with COPD include current smoking, older age, low body mass index 

(BMI) and severe COPD. 

 

Ethnic populations 

Data from a large clinical trial (the Salmeterol Multi-Center Asthma Research Trial, SMART) suggested 

African-American patients were at increased risk of serious respiratory-related events or deaths when using 

salmeterol compared with placebo (see section 5.1). It is not known if this was due to pharmacogenetic or 

other factors. Patients of black African or Afro-Caribbean ancestry should therefore be asked to continue 

treatment but to seek medical advice if asthma symptoms remain uncontrolled or worsen whilst using 

Aerivio Spiromax. 

 

Paediatric Population 

 

Aerivio Spiromax is not indicated for use in children and adolescents under the age of 18 years (see Section 

4.2). However, it should be noted that children and adolescents less than 16 years taking high doses of 

fluticasone propionate (typically ≥ 1000 micrograms/day) may be at particular risk.  Systemic effects may 

occur, particularly at high doses prescribed for long periods.  Possible systemic effects include Cushing's 

syndrome, Cushingoid features, adrenal suppression, acute adrenal crisis and growth retardation in children 

and adolescents and more rarely, a range of psychological or behavioural effects including psychomotor 

hyperactivity, sleep disorders, anxiety, depression or aggression.  Consideration should be given to referring 

the child or adolescent to a paediatric respiratory specialist.  It is recommended that the height of children 

receiving prolonged treatment with inhaled corticosteroids is regularly monitored. The dose of inhaled 

corticosteroid should always be reduced to the lowest dose at which effective control of asthma is maintained. 

 

Oral infections 

Due to the fluticasone propionate component, hoarseness and candidiasis (thrush) of the mouth and throat 

and, rarely of the oesophagus, can occur in some patients. Both hoarseness and the incidence of candidiasis 

of the mouth and throat may be relieved by rinsing the mouth with water and spitting the water out and/or 

Me
dic

ina
l p

ro
du

ct 
no

 lo
ng

er
 au

th
or

ise
d



8 

brushing the teeth after using the product. Symptomatic candidiasis of the mouth and throat can be treated 

with topical anti-fungal therapy whilst still continuing with Aerivio Spiromax. 

 

Excipients 

This medicinal product contains lactose. Patients with severe lactose intolerance should use this medicine 

with caution and those with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or 

glucose-galactose malabsorption should not take this medicine. The excipient lactose may contain small 

amounts of milk proteins which may cause allergic reactions in those with severe hypersensitivity or allergy 

to milk protein. 

 

4.5 Interaction with other medicinal products and other forms of interaction 

 

Beta adrenergic blockers may weaken or antagonise the effect of salmeterol. Both non-selective and selective 

β blockers should be avoided unless there are compelling reasons for their use. Potentially serious 

hypokalaemia may result from β2 agonist therapy. Particular caution is advised in acute severe asthma as this 

effect may be potentiated by concomitant treatment with xanthine derivatives, steroids and diuretics. 

 

Concomitant use of other β adrenergic-containing medicinal products can have a potentially additive effect. 

 

Salmeterol 

Potent CYP3A4 inhibitors 

Co-administration of ketoconazole (400 mg orally once daily) and salmeterol (50 micrograms inhaled twice 

daily) in 15 healthy subjects for 7 days resulted in a significant increase in plasma salmeterol exposure (1.4-

fold Cmax and 15-fold AUC). This may lead to an increase in the incidence of other systemic effects of 

salmeterol treatment (e.g. prolongation of QTc interval and palpitations) compared with salmeterol or 

ketoconazole treatment alone (see section 4.4). 

 

Clinically significant effects were not seen on blood pressure, heart rate, blood glucose and blood potassium 

levels. Co-administration with ketoconazole did not increase the elimination half-life of salmeterol or 

increase salmeterol accumulation with repeat dosing. 

 

The concomitant administration of ketoconazole should be avoided, unless the benefits outweigh the 

potentially increased risk of systemic effects of salmeterol treatment. There is likely to be a similar risk of 

interaction with other potent CYP3A4 inhibitors (e.g. itraconazole, telithromycin, ritonavir). 

 

Moderate CYP 3A4 inhibitors 

Co-administration of erythromycin (500 mg orally three times a day) and salmeterol (50 micrograms inhaled 

twice daily) in 15 healthy subjects for 6 days resulted in a small but non-statistically significant increase in 

salmeterol exposure (1.4-fold Cmax and 1.2-fold AUC). Co-administration with erythromycin was not 

associated with any serious adverse effects. 

 

Fluticasone propionate 

Under normal circumstances, low plasma concentrations of fluticasone propionate are achieved after inhaled 

dosing, due to extensive first pass metabolism and high systemic clearance mediated by cytochrome P450 

3A4 in the gut and liver. Hence, clinically significant drug interactions mediated by fluticasone propionate 

are unlikely. 

 

In an interaction study in healthy subjects with intranasal fluticasone propionate, ritonavir (a highly potent 

cytochrome P450 3A4 inhibitor) 100 mg twice daily increased the fluticasone propionate plasma 

concentrations several hundred fold, resulting in markedly reduced serum cortisol concentrations. 

Information about this interaction is lacking for inhaled fluticasone propionate, but a marked increase in 

fluticasone propionate plasma levels is expected. Cases of Cushing’s syndrome and adrenal suppression have 

been reported. The combination should be avoided unless the benefit outweighs the increased risk of 

systemic glucocorticoid undesirable effects. 

 

Me
dic

ina
l p

ro
du

ct 
no

 lo
ng

er
 au

th
or

ise
d



9 

In a small study in healthy volunteers, the slightly less potent CYP3A inhibitor ketoconazole increased the 

exposure of fluticasone propionate after a single inhalation by 150%. This resulted in a greater reduction of 

plasma cortisol as compared with fluticasone propionate alone. Co-treatment with other potent CYP3A 

inhibitors, such as itraconazole, and moderate CYP3A inhibitors, such as erythromycin, is also expected to 

increase the systemic fluticasone propionate exposure and the risk of systemic undesirable effects. Caution is 

recommended and long-term treatment with such drugs should if possible be avoided. 

 

Co-treatment with CYP3A inhibitors, including cobicistat-containing products, is expected to increase the 

risk of systemic side-effects. The combination should be avoided unless the benefit outweighs the increased 

risk of systemic corticosteroid side-effects, in which case patients should be monitored for systemic 

corticosteroid effects. 

 

 

 

4.6 Fertility, pregnancy and lactation 

 

Pregnancy 

A moderate amount of data on pregnant women (between 300 to 1000 pregnancy outcomes) indicates no 

malformative or feto/neonatal toxicity of salmeterol and fluticasone propionate. Animal studies have shown 

reproductive toxicity after administration of β2 adrenoreceptor agonists and glucocorticosteroids (see section 

5.3). 
 

Administration of Aerivio Spiromax to pregnant women should only be considered if the expected benefit to 

the mother is greater than any possible risk to the fetus. 

 

The lowest effective dose of fluticasone propionate needed to maintain adequate asthma control should be 

used in the treatment of pregnant women. 

 

Breastfeeding 

It is unknown whether salmeterol and fluticasone propionate /metabolites are excreted in human milk.  

 

Studies have shown that salmeterol and fluticasone propionate and their metabolites, are excreted into the 

milk of lactating rats.  

 

A risk to breastfed newborns/infants cannot be excluded. A decision must be made whether to discontinue 

breastfeeding or to discontinue Aerivio Spiromax therapy taking into account the benefit of breastfeeding for 

the child and the benefit of therapy for the woman. 

 

Fertility 

There are no data in humans. However, animal studies showed no effects of salmeterol or fluticasone 

propionate on fertility. 

 

 

4.7 Effects on ability to drive and use machines 

 

Aerivio Spiromax has no or negligible influence on the ability to drive and use machines. 

 

4.8 Undesirable effects 

 

Summary of safety profile 

As Aerivio Spiromax contains salmeterol and fluticasone propionate, the type and severity of adverse 

reactions associated with each of the active substance may be expected. There is no incidence of additional 

adverse events following concurrent administration of the two active substances. 

 

Adverse reactions which have been associated with salmeterol/fluticasone propionate are given below, listed 

by system organ class and frequency. Frequencies are defined as: very common (≥1/10), common (1/100 to 

Me
dic

ina
l p

ro
du

ct 
no

 lo
ng

er
 au

th
or

ise
d



10 

1/10), uncommon (1/1000 to 1/100), rare (1/10,000 to <1/1000) and not known (frequency cannot be 

estimated from the available data). Frequencies were derived from clinical trial data. The incidence in 

placebo was not taken into account. 

 

System Organ Class Adverse reaction Frequency 

Infections and 

infestations  

Candidiasis of the mouth and throat 

 

Pneumonia (in COPD patients) 

 

Bronchitis 

 

Oesophageal candidiasis 

Common 

 

Common
1,3,5

 

 

Common
1,3 

 

Rare 

Immune system 

disorders  

Hypersensitivity reactions with the following 

manifestations: 

 

Cutaneous hypersensitivity reactions 

 

Angioedema (mainly facial and oropharyngeal 

oedema) 

  

Respiratory symptoms (dyspnoea)  

 

Respiratory symptoms (bronchospasm) 

 

Anaphylactic reactions including anaphylactic shock 

 

 

 

 

Uncommon 

 

Rare 

 

 

Uncommon 

 

Rare 

 

Rare 

Endocrine disorders  Cushing’s syndrome, Cushingoid features, Adrenal 

suppression, Growth retardation in children and 

adolescents, Decreased bone mineral density 

 

Rare
4
 

Metabolism and 

nutrition disorders  

Hypokalaemia 

 

Hyperglycaemia 

 

Common
3
 

 

Uncommon
4
 

Psychiatric disorders  Anxiety  

 

Sleep disorders  

 

Behavioural changes, including psychomotor 

hyperactivity and irritability (predominantly in 

children) 

 

Depression, aggression (predominantly in children) 

 

Uncommon 

 

Uncommon 

 

Rare 

 

 

 

Not known  

Nervous system 

disorders  

Headache 

 

Tremor 

 

Very Common
1
 

 

Uncommon 

Eye disorders Cataract  

 

Glaucoma 

 

Vision, blurred (see also section 4.4) 

 

 

Uncommon 

 

Rare
4 

 

Not Known 

Me
dic

ina
l p

ro
du

ct 
no

 lo
ng

er
 au

th
or

ise
d



11 

System Organ Class Adverse reaction Frequency 

Cardiac disorders  Palpitations 

 

Tachycardia 

 

Cardiac arrhythmias (including supraventricular 

tachycardia and extrasystoles). 

 

Atrial fibrillation 

 

Angina pectoris 

 

Uncommon 

 

Uncommon 

 

Rare 

 

 

Uncommon 

 

Uncommon 

Respiratory, thoracic 

and mediastinal 

disorders  

Nasopharyngitis 

 

Throat irritation 

 

Hoarseness/dysphonia 

 

Sinusitis 

 

Paradoxical bronchospasm 

 

Very Common
2,3

 

 

Common 

 

Common 

 

Common
1,3

 

 

Rare
4
 

Skin and 

subcutaneous tissue 

disorders  

 

Contusions Common
1,3

 

Musculoskeletal and 

connective tissue 

disorders  

Muscle cramps 

 

Traumatic fractures 

 

Arthralgia 

 

Myalgia 

 

Common 

 

Common
1,3

 

 

Common 

 

Common 

1. Reported commonly in placebo 

2. Reported very commonly in placebo 

3. Reported over 3 years in a COPD study 

4. See section 4.4 

5. See section 5.1. 

 

Description of selected adverse reactions 

 

The pharmacological effects of β2 agonist treatment, such as tremor, palpitations and headache, have been 

reported, but tend to be transient and reduce with regular therapy. 

 

Paradoxical bronchospasm may occur with an immediate increase in wheezing and shortness of breath after 

dosing. Paradoxical bronchospasm responds to a rapid-acting bronchodilator and should be treated 

straightaway. Aerivio Spiromax should be discontinued immediately, the patient assessed and alternative 

therapy instituted if necessary. 

 

Due to the fluticasone propionate component, hoarseness and candidiasis (thrush) of the mouth and throat 

and, rarely, of the oesophagus, can occur in some patients. Both hoarseness and incidence of mouth and 

throat candidiasis may be relieved by rinsing the mouth with water and spitting the water out and/or brushing 

the teeth after using the product. Symptomatic mouth and throat candidiasis can be treated with topical anti-

fungal therapy whilst still continuing with Aerivio Spiromax. 

Me
dic

ina
l p

ro
du

ct 
no

 lo
ng

er
 au

th
or

ise
d



12 

 

Paediatric population 

Aerivio Spiromax is not indicated for use in children and adolescents under the age of 18 years (see Section 

4.2). Possible systemic effects in these age groups include Cushing's syndrome, Cushingoid features, adrenal 

suppression and growth retardation in children and adolescents (see section 4.4). Children may also 

experience anxiety, sleep disorders and behavioural changes, including hyperactivity and irritability.  

 

Reporting of suspected adverse reactions 

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows 

continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked 

to report any suspected adverse reactions via the national reporting system listed in Appendix V. 

 

4.9 Overdose 

 

There are no data available from clinical trials on overdose with Aerivio Spiromax, however data on 

overdose with both active substances are given below: 

 

Salmeterol 

The signs and symptoms of salmeterol overdose are dizziness, increases in systolic blood pressure, tremor, 

headache and tachycardia. If Aerivio Spiromax therapy has to be withdrawn due to overdose of the β agonist 

component of the medicinal product, provision of appropriate replacement steroid therapy should be 

considered. Additionally, hypokalaemia can occur and therefore serum potassium levels should be 

monitored. Potassium replacement should be considered. 

 

Fluticasone propionate  

Acute: Acute inhalation of fluticasone propionate doses in excess of those recommended may lead to 

temporary suppression of adrenal function. This does not need emergency action as adrenal function is 

recovered in a few days, as verified by plasma cortisol measurements. 

 

Chronic overdose: Adrenal reserve should be monitored and treatment with a systemic corticosteroid may be 

necessary. When stabilised, treatment should be continued with an inhaled corticosteroid at the 

recommended dose. See section 4.4: “Adrenal function”.  

 

In cases of both acute and chronic fluticasone propionate overdose Aerivio Spiromax therapy should be 

continued at a suitable dose for symptom control. 

 

 

5. PHARMACOLOGICAL PROPERTIES 

 

5.1  Pharmacodynamic properties 

 

Pharmacotherapeutic group: Drugs for obstructive airway diseases, adrenergics in combination with 

corticosteroids or other drugs, excl. anticholinergics, ATC code: R03AK06 

 

Mechanism of action and pharmacodynamic effects 

Aerivio Spiromax contains salmeterol and fluticasone propionate, which have differing modes of action. 

The respective mechanisms of action of both active substances are discussed below. 

 

Salmeterol: 

Salmeterol is a selective long-acting (12 hour) β2 adrenoceptor agonist with a long side chain which binds to 

the exo-site of the receptor. 

Salmeterol produces a longer duration of bronchodilation, lasting for at least 12 hours, than recommended 

doses of conventional short-acting β2 agonists. 

 

Me
dic

ina
l p

ro
du

ct 
no

 lo
ng

er
 au

th
or

ise
d



13 

Fluticasone propionate: 

Fluticasone propionate given by inhalation at recommended doses has a glucocorticoid anti-inflammatory 

action within the lungs, resulting in reduced symptoms and exacerbations of asthma, with less adverse effects 

than when corticosteroids are administered systemically. 

 

Clinical efficacy and safety 

 

The studies described below (GOAL, TORCH and SMART) were carried out with this same fixed-dose 

combination, salmeterol xinafoate and fluticasone propionate, but studied a previously authorised product; 

the studies described were not carried out with Aerivio Spiromax. 

 

Salmeterol/Fluticasone propionate - Asthma clinical trials  

A twelve month study (Gaining Optimal Asthma ControL, GOAL), in 3416 adult and adolescent patients 

with persistent asthma, compared the safety and efficacy of salmeterol/fluticasone propionate versus inhaled 

corticosteroid (fluticasone propionate) alone to determine whether the goals of asthma management were 

achievable. Treatment was stepped up every 12 weeks until **total control was achieved or the highest dose 

of study drug was reached. GOAL showed more patients treated with salmeterol/fluticasone propionate 

achieved asthma control than patients treated with inhaled corticosteroid (ICS) alone and this control was 

attained at a lower corticosteroid dose. 

 

*Well controlled asthma was achieved more rapidly with salmeterol/fluticasone propionate than with ICS 

alone. The time on treatment for 50% of subjects to achieve a first individual well controlled week was 16 

days for salmeterol/fluticasone propionate compared with 37 days for the ICS group. In the subset of steroid 

naive asthmatics the time to an individual well controlled week was 16 days in the salmeterol/fluticasone 

propionate treatment compared with 23 days following treatment with ICS. 

 

The overall study results showed: 

 

Percentage of Patients Attaining *Well Controlled (WC) and **Totally Controlled (TC) Asthma over 

12 months 

 

Pre-Study Treatment  

Salmeterol/FP FP 

WC TC WC TC 

No ICS (SABA alone) 78% 50% 70% 40% 

Low dose ICS ( ≤500 micrograms BDP or 

equivalent/day) 

75% 44% 60% 28% 

Medium dose ICS (>500 to 1000 micrograms 

BDP or equivalent/day) 

62% 29% 47% 16% 

Pooled results across the 3 treatment levels 71% 41% 59% 28% 

*Well controlled asthma - less than or equal to 2 days with symptom score greater than 1 (symptom score 1 

defined as ‘symptoms for one short period during the day’), SABA use on less than or equal to 2 days and 

less than or equal to 4 occasions/week, greater than or equal to 80% predicted morning peak expiratory flow, 

no night-time awakenings, no exacerbations and no side effects enforcing a change in therapy  

**Total control of asthma - no symptoms, no SABA use, greater than or equal to 80% predicted morning 

peak expiratory flow, no night-time awakenings, no exacerbations and no side effects enforcing a change in 

therapy 

 

The results of this study suggest that salmeterol/fluticasone propionate 50/100 micrograms twice daily may 

be considered as initial maintenance therapy in patients with moderate persistent asthma for whom rapid 

control of asthma is deemed essential (see section 4.2). 

 

A double blind, randomised, parallel group study in 318 patients with persistent asthma aged ≥18 years 

evaluated the safety and tolerability of administering two inhalations twice daily (double dose) of 

salmeterol/fluticasone propionate for two weeks. The study showed that doubling the inhalations of each 

strength of salmeterol/fluticasone propionate for up to 14 days resulted in a small increase in β agonist-

related adverse events (tremor - 1 patient [1%] vs 0, palpitations - 6 [3%] vs 1 [<1%], muscle cramps –6 

Me
dic

ina
l p

ro
du

ct 
no

 lo
ng

er
 au

th
or

ise
d



14 

[3%] vs 1 [<1%]) and a similar incidence of inhaled corticosteroid related adverse events (e.g. oral 

candidiasis - 6 [6%] vs 16 [8%], hoarseness - 2 [2%] vs 4 [2%]) compared with one inhalation twice daily. 

The small increase in β agonist-related adverse events should be taken into account if doubling the dose of 

salmeterol/fluticasone propionate is considered by the physician in adult patients requiring additional short-

term (up to 14 days) inhaled corticosteroid therapy. 

 

Salmeterol/fluticasone propionate COPD - clinical trials 

TORCH was a 3-year study to assess the effect of treatment with salmeterol/fluticasone propionate 

inhalation powder 50/500 micrograms twice daily, salmeterol inhalation powder 50 micrograms twice daily, 

fluticasone propionate (FP) inhalation powder 500 micrograms twice daily or placebo on all-cause mortality 

in patients with COPD. COPD patients with a baseline (pre-bronchodilator) FEV1 <60% of predicted normal 

were randomised to double-blind medication. During the study, patients were permitted usual COPD therapy 

with the exception of other inhaled corticosteroids, long-acting bronchodilators and long-term systemic 

corticosteroids. Survival status at 3 years was determined for all patients regardless of withdrawal from study 

medication. The primary endpoint was reduction in all-cause mortality at 3 years for salmeterol/fluticasone 

propionate vs placebo.  

 

 
Placebo 

N = 1524 

Salmeterol 50 

N = 1521 

FP 500 

N = 1534 

Salmeterol/fluticasone 

propionate 50/500 

N = 1533 

All cause mortality at 3 years 

Number of deaths (%) 
231 

(15.2%) 

205 

(13.5%)  

246 

(16.0%) 

193 

(12.6%) 

Hazard Ratio vs 

Placebo (CIs) 

p value 

N/A 

0.879  

(0.73, 1.06) 

0.180 

1.060 

(0.89, 1.27) 

0.525 

0.825 

(0.68, 1.00 ) 

0.052
1 

Hazard Ratio 

fluticasone 

propionate/salmeterol 

500/50 vs components 

(CIs) 

p value 

N/A 

0.932  

(0.77, 1.13) 

0.481 

0.774 

(0.64, 0.93) 

0.007 

N/A 

1. Non-significant p value after adjustment for 2 interim analyses on the primary efficacy comparison from a 

log-rank analysis stratified by smoking status 

 

There was a trend towards improved survival in subjects treated with salmeterol/fluticasone propionate 

compared with placebo over 3 years however this did not achieve the statistical significance level p≤0.05. 

 

The percentage of patients who died within 3 years due to COPD-related causes was 6.0% for placebo, 6.1% 

for salmeterol, 6.9% for FP and 4.7% for salmeterol/fluticasone propionate. 

 

The mean number of moderate to severe exacerbations per year was significantly reduced with 

salmeterol/fluticasone propionate (FP) as compared with treatment with salmeterol, FP and placebo (mean 

rate in the salmeterol/fluticasone propionate group 0.85 compared with 0.97 in the salmeterol group, 0.93 in 

the FP group and 1.13 in the placebo). This translates to a reduction in the rate of moderate to severe 

exacerbations of 25% (95% CI: 19% to 31%; p<0.001) compared with placebo, 12% compared with 

salmeterol (95% CI: 5% to 19%, p=0.002) and 9% compared with FP (95% CI: 1% to 16%, p=0.024). 

Salmeterol and FP significantly reduced exacerbation rates compared with placebo by 15% (95% CI: 7% to 

22%; p<0.001) and 18% (95% CI: 11% to 24%; p<0.001) respectively.  

 

Health Related Quality of Life, as measured by the St George’s Respiratory Questionnaire (SGRQ) was 

improved by all active treatments in comparison with placebo. The average improvement over three years for 

salmeterol/fluticasone propionate compared with placebo was -3.1 units (95% CI: -4.1 to -2.1; p<0.001) and 

when compared with salmeterol was -2.2 units (p<0.001) and when compared with FP was -1.2 units 

(p=0.017). A 4-unit decrease is considered clinically relevant. 

Me
dic

ina
l p

ro
du

ct 
no

 lo
ng

er
 au

th
or

ise
d



15 

 

The estimated 3-year probability of having pneumonia reported as an adverse event was 12.3% for placebo, 

13.3% for salmeterol, 18.3% for FP and 19.6% for salmeterol/fluticasone propionate (hazard ratio for 

salmeterol/fluticasone propionate vs placebo: 1.64, 95% CI: 1.33 to 2.01, p<0.001). There was no increase in 

pneumonia related deaths; deaths while on treatment that were adjudicated as primarily due to pneumonia 

were 7 for placebo, 9 for salmeterol, 13 for FP and 8 for salmeterol/fluticasone propionate. There was no 

significant difference in probability of bone fracture (5.1% placebo, 5.1% salmeterol, 5.4% FP and 6.3% 

salmeterol/fluticasone propionate; hazard ratio for salmeterol/fluticasone propionate vs placebo: 1.22, 95% 

CI: 0.87 to 1.72, p=0.248.  

 

Placebo-controlled clinical trials, over 6 and 12 months, have shown that regular use of 

salmeterol/fluticasone propionate 50/500 micrograms improves lung function and reduces breathlessness and 

the use of relief medication.  

 

Studies SCO40043 and SCO100250 were randomised, double-blind, parallel-group, replicate studies 

comparing the effect of salmeterol/fluticasone propionate 50/250 micrograms twice daily (a dose not 

licensed for COPD treatment in the European Union) with salmeterol 50 micrograms twice daily, on the 

annual rate of moderate/severe exacerbations in subjects with COPD with FEV1 less than 50% predicted and 

a history of exacerbations. Moderate/ severe exacerbations were defined as worsening symptoms that 

required treatment with oral corticosteroids and/or antibiotics or in-patient hospitalisation. 

 

The trials had a 4 week run-in period during which all subjects received open-label salmeterol/FP 50/250 to 

standardize COPD pharmacotherapy and stabilise disease prior to randomisation to blinded study medication 

for 52 weeks. Subjects were randomised 1:1 to salmeterol/FP 50/250 (total ITT n=776) or salmeterol (total 

ITT n=778). Prior to run-in, subjects discontinued use of previous COPD medications except short-acting 

bronchodilators. The use of concurrent inhaled long-acting β2 agonists and anticholinergic drugs, 

salbutamol/ipratropium bromide combination products, oral β2 agonists and theophylline preparations were 

not allowed during the treatment period. Oral corticosteroids and antibiotics were allowed for the acute 

treatment of COPD exacerbations with specific guidelines for use. Subjects used salbutamol on an as-needed 

basis throughout the studies. 

 

The results of both studies showed that treatment with salmeterol/fluticasone propionate 50/250 resulted in a 

significantly lower annual rate of moderate/severe COPD exacerbations compared with salmeterol 

(SCO40043: 1.06 and 1.53 per subject per year, respectively, rate ratio of 0.70, 95% CI: 0.58 to 0.83, 

p<0.001; SCO100250: 1.10 and 1.59 per subject per year, respectively, rate ratio of 0.70, 95% CI: 0.58 to 

0.83, p<0.001). Findings for the secondary efficacy measures (time to first moderate/severe exacerbation, the 

annual rate of exacerbations requiring oral corticosteroids, and pre-dose morning (AM) FEV1) significantly 

favoured salmeterol/fluticasone propionate 50/250 micrograms twice daily over salmeterol. Adverse event 

profiles were similar with the exception of a higher incidence of pneumonias and known local side effects 

(candidiasis and dysphonia) in the salmeterol/fluticasone propionate 50/250 micrograms twice daily group 

compared with salmeterol. Pneumonia-related events were reported for 55 (7%) subjects in the 

salmeterol/fluticasone propionate 50/250 micrograms twice daily group and 25 (3%) in the salmeterol group. 

The increased incidence of reported pneumonia with salmeterol/fluticasone propionate 50/250 micrograms 

twice daily appears to be of similar magnitude to the incidence reported following treatment with 

salmeterol/fluticasone propionate 50/500 micrograms twice daily in TORCH. 

 

The Salmeterol Multi-center Asthma Research Trial (SMART)  

SMART was a multi-centre, randomised, double blind, placebo-controlled, parallel group 28-week study in 

the US which randomised 13,176 patients to salmeterol (50 micrograms twice daily) and 13,179 patients to 

placebo in addition to the patients’ usual asthma therapy. Patients were enrolled if ≥12 years of age, with 

asthma and if currently using asthma medication (but not a LABA). Baseline ICS use at study entry was 

recorded, but not required in the study. The primary endpoint in SMART was the combined number of 

respiratory-related deaths and respiratory-related life-threatening experiences.  

 

Me
dic

ina
l p

ro
du

ct 
no

 lo
ng

er
 au

th
or

ise
d



16 

Key findings from SMART: primary endpoint 

Patient group Number of primary endpoint events 

/number of patients 

Relative Risk 

(95% confidence 

intervals) salmeterol  placebo 

All patients 50/13,176 36/13,179 1.40 (0.91, 2.14) 

Patients using inhaled steroids 23/6,127 19/6,138 1.21 (0.66, 2.23) 

Patients not using inhaled steroids 27/7,049 17/7,041 1.60 (0.87, 2.93) 

African-American patients 20/2,366 5/2,319 4.10 (1.54, 10.90) 

(Risk in bold is statistically significant at the 95% level.) 

 

 

 

 

 

 

 

 

 

Key findings from SMART by inhaled steroid use at baseline: secondary endpoints 

 Number of secondary endpoint 

events/number of patients 

Relative Risk 

(95% confidence 

intervals) salmeterol  placebo 

Respiratory -related death 

Patients using inhaled steroids 10/6127 5/6138 2.01 (0.69, 5.86) 

Patients not using inhaled steroids 14/7049 6/7041 2.28 (0.88, 5.94) 

Combined asthma-related death or life-threatening experience 

Patients using inhaled steroids 16/6127 13/6138 1.24 (0.60, 2.58) 

Patients not using inhaled steroids 21/7049 9/7041 2.39 (1.10, 5.22) 

Asthma-related death 

Patients using inhaled steroids 4/6127 3/6138 1.35 (0.30, 6.04) 

Patients not using inhaled steroids 9/7049 0/7041 * 

(*=could not be calculated because of no events in placebo group. Risk in bold figures is statistically 

significant at the 95% level. The secondary endpoints in the table above reached statistical significance in the 

whole population.) The secondary endpoints of combined all cause death or life-threatening experience, all 

cause death, or all cause hospitalisation did not reach statistical significance in the whole population. 

 

Peak Inspiratory Flow Rate through the Spiromax Device 

A randomised, open-label cross-over study was performed in children and adolescents with asthma (aged 4-

17 years), adults with asthma (aged 18-45 years), adults with chronic obstructive pulmonary disease (COPD) 

(aged older than 55 years) and healthy volunteers (aged 18-45 years) to evaluate the peak inspiratory flow 

rate (PIFR) and other related inhalation parameters following inhalation from a Spiromax device (containing 

placebo) compared with inhalation from an already marketed multi-dose dry powder inhaler device 

(containing placebo). The impact of optimal training (i.e. breathing in forcefully upon inhalation) in dry 

powder inhaler inhalation technique on inhalation speed and volume was assessed in these subject groups, 

together with assessment of potential differences in inhalation outputs according to the devices used.  

 

The data from the study indicated that regardless of age and underlying disease severity, children, 

adolescents and adults with asthma as well as patients with COPD were able to achieve inspiratory flow rates 

through the Spiromax device that were similar to those generated through the marketed multi-dose dry 

powder inhaler device. The mean PIFR achieved by patients with asthma or COPD with optimal training (i.e. 

forceful inhalation) was over 60 L/min, a flow rate at which both devices studied are known to deliver 

comparable amounts of drug to the lungs.  

 

All subjects with asthma or COPD achieved PIFR values greater than 60L/min after optimal training. It is 

important to inhale forcefully to ensure optimal dosing. 

Me
dic

ina
l p

ro
du

ct 
no

 lo
ng

er
 au

th
or

ise
d



17 

 

A  flow rate of greater than 60L/min is required for optimal delivery of drugs to the lungs through the multi-

dose dry powder Spiromax inhaler.  

 

In order to ensure that patients achieve the PIFR needed to deliver the required dose, the patient is required to 

be trained on the use of the Spiromax device including instruction on the need to inhale forcefully (see 

Section 4.2). 

 

Paediatric population 

Aerivio Spiromax is not recommended for use in children and adolescents aged less than 18 years. The 

safety and efficacy of Aerivio Spiromax in this young population have not been established.  The data 

presented below refer to a lower dose of the fixed-dose combination containing these two actives, a dose and 

strength which is not available for Aerivio Spiromax. The studies described were carried out with a 

previously authorised product available in three different strengths; the studies were not carried out with 

Aerivio Spiromax. 

 

In a study  in 158 children aged 6 to 16 years with symptomatic asthma, the combination of salmeterol/ 

fluticasone propionate is as efficacious as doubling the dose of fluticasone propionate in respect of  symptom 

control and lung function. This study was not designed to investigate the effect on exacerbations. 

 

In a 12-week trial of children aged 4 to 11 years [n=257] treated with either salmeterol/fluticasone 

propionate 50/100 or salmeterol 50 micrograms + fluticasone propionate 100 micrograms both twice daily, 

both treatment arms experienced a 14% increase in peak expiratory flow rate as well as improvements in 

symptom score and rescue salbutamol use. There were no differences between the two treatment arms. There 

were no differences in safety parameters between the two treatment arms. 

 

In a 12-week trial of children 4 to 11 years of age [n=203] randomized in a parallel-group study with 

persistent asthma and who were symptomatic on inhaled corticosteroid, safety was the primary objective. 

Children received either salmeterol/fluticasone propionate (50/100 micrograms) or fluticasone propionate 

(100 micrograms) alone twice daily. Two children on salmeterol/fluticasone propionate and 5 children on 

fluticasone propionate withdrew because of worsening asthma. After 12 weeks no children in either 

treatment arm had abnormally low 24-hour urinary cortisol excretion. There were no other differences in 

safety profile between the treatment arms. 

 

5.2 Pharmacokinetic properties 

 

For pharmacokinetic purposes each component can be considered separately. 

 

Salmeterol 

Salmeterol acts locally in the lung therefore plasma levels are not an indication of therapeutic effects. In 

addition there are only limited data available on the pharmacokinetics of salmeterol because of the technical 

difficulty of assaying the drug in plasma due to the low plasma concentrations at therapeutic doses 

(approximately 200 picogram/mL or less) achieved after inhaled dosing. 

 

 

Fluticasone propionate 

The absolute bioavailability of a single dose of inhaled fluticasone propionate in healthy subjects varies 

between approximately 5 to 11% of the nominal dose depending on the inhalation device used. In patients 

with asthma or COPD a lesser degree of systemic exposure to inhaled fluticasone propionate has been 

observed. 

 

Absorption 

Systemic absorption occurs mainly through the lungs and is initially rapid then prolonged. The remainder of 

the inhaled dose of fluticasone propionate may be swallowed but contributes minimally to systemic exposure 

due to the low aqueous solubility and presystemic metabolism, resulting in oral availability of less than 1%. 

There is a linear increase in systemic exposure with increasing inhaled dose. 

Me
dic

ina
l p

ro
du

ct 
no

 lo
ng

er
 au

th
or

ise
d



18 

 

Distribution 

The disposition of fluticasone propionate is characterised by high plasma clearance (1150 mL/min), a large 

volume of distribution at steady-state (approximately 300 L) and a terminal half-life of approximately 8 

hours. Plasma protein binding is 91%.  

 

Biotransformation 

Fluticasone propionate is cleared very rapidly from the systemic circulation. The main pathway is 

metabolism to an inactive carboxylic acid metabolite, by the cytochrome P450 enzyme CYP3A4. Other 

unidentified metabolites are also found in the faeces.  

 

Elimination 

The renal clearance of fluticasone propionate is negligible. Less than 5% of the dose is excreted in urine, 

mainly as metabolites. The main part of the dose is excreted in faeces as metabolites and unchanged drug. 

 

Paediatric population 

 

Aerivio Spiromax is not recommended for use in children and adolescents aged less than 18 years. The 

safety and efficacy of Aerivio Spiromax in this young population have not been established.  The data 

presented below refer to a lower dose of the fixed-dose combination containing these two actives, a dose and 

strength which is not available for Aerivio Spiromax. 

 

In a population pharmacokinetic analysis from 9 controlled clinical trials of 350 patients with asthma aged 4 

to 77 years (174 patients 4 to 11 years of age) higher fluticasone propionate systemic exposure following 

treatment with salmeterol/fluticasone propionate inhalation powder 50/100 compared with fluticasone 

propionate inhalation powder 100 was seen. 

 

 

5.3 Preclinical safety data 

 

The only safety concerns for human use derived from animal studies of salmeterol and fluticasone propionate 

given separately were effects associated with exaggerated pharmacological actions. 

 

In animal reproduction studies, glucocorticosteroids have been shown to induce malformations (cleft palate, 

skeletal malformations). However, these animal experimental results do not seem to be relevant for man 

given recommended doses. Animal studies with salmeterol have shown embryofetal toxicity only at high 

exposure levels. Following co-administration, increased incidences of transposed umbilical artery and 

incomplete ossification of occipital bone were found in rats at doses associated with known glucocorticoid-

induced abnormalities. 

 

 

6. PHARMACEUTICAL PARTICULARS 

 

6.1 List of excipients 

 

Lactose monohydrate. 

 

6.2 Incompatibilities 

 

Not applicable. 

 

6.3 Shelf life 

 

2 years.   

After opening the foil wrap: 3 months.  

 

Me
dic

ina
l p

ro
du

ct 
no

 lo
ng

er
 au

th
or

ise
d



19 

 

6.4 Special precautions for storage 

 

Do not store above 25C.  

Keep the mouthpiece cover closed after removal of the foil wrap.  

 

6.5 Nature and contents of container  

 

The inhaler is white with a semi-transparent yellow mouthpiece cover. The drug/mucosal contact parts of the 

inhaler are made of acrylonitrile butadiene styrene (ABS), polyethylene (PE) , and polypropylene (PP). Each 

inhaler contains 60 doses and is foil-wrapped. 

 

Pack sizes of 1 or 3 inhalers. 

 

Not all pack-sizes may be marketed. 

 

6.6 Special precautions for disposal and other handling 

 

No special requirements. 

 

 

7. MARKETING AUTHORISATION HOLDER 

 

Teva B.V., 

Swensweg 5, 

2031 GA Haarlem  

Netherlands 

 

 

8. MARKETING AUTHORISATION NUMBER(S)  

 

EU/1/16/1122/001 

EU/1/16/1122/002 

 

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION 

 

Date of first authorisation: 18
th
 August 2016 

 

 

10. DATE OF REVISION OF THE TEXT 

 

Detailed information on this medicinal product is available on the website of the European Medicines 

Agency http://www.ema.europa.eu 

 

Me
dic

ina
l p

ro
du

ct 
no

 lo
ng

er
 au

th
or

ise
d



20 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ANNEX II 

 

A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE 

 

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND 

USE 

 

C. OTHER CONDITIONS AND REQUIREMENTS OF THE 

MARKETING AUTHORISATION 

 

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE 

SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT 

 

Me
dic

ina
l p

ro
du

ct 
no

 lo
ng

er
 au

th
or

ise
d



21 

A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE 

 

Name and address of the manufacturer(s) responsible for batch release 

 

Norton (Waterford) Limited 

T/A Teva Pharmaceuticals Ireland 

Unit 27/35 IDA Industrial Park 

Cork Road 

Waterford 

Ireland 

 

Teva Pharmaceuticals Europe B.V. 

Swensweg 5 

2031 GA Haarlem 

The Netherlands 

 

Teva Operations Poland Sp. z.o.o. 

ul. Mogilska 80 

31-546 Kraków 

Poland 

 

The printed package leaflet of the medicinal product must state the name and address of the manufacturer 

responsible for the release of the concerned batch. 

 

 

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE  

 

Medicinal product subject to medical prescription. 

 

 

 

C.  OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION 

 

 Periodic Safety Update Reports 

 

The requirements for submission of periodic safety update reports for this medicinal product are set out in 

the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC 

and any subsequent updates published on the European medicines web-portal. 

The marketing authorisation holder shall submit the first periodic safety update report for this product within 

6 months following authorisation. 

 

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE 

OF THE MEDICINAL PRODUCT   

 

 Risk Management Plan (RMP) 

 

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the 

agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent 

updates of the RMP. 

 

An updated RMP should be submitted: 

 At the request of the European Medicines Agency; 

Me
dic

ina
l p

ro
du

ct 
no

 lo
ng

er
 au

th
or

ise
d



22 

 Whenever the risk management system is modified, especially as the result of new information being 

received that may lead to a significant change to the benefit/risk profile or as the result of an important 

(pharmacovigilance or risk minimisation) milestone being reached. 

 

 

 

Me
dic

ina
l p

ro
du

ct 
no

 lo
ng

er
 au

th
or

ise
d



23 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ANNEX III 

 

LABELLING AND PACKAGE LEAFLET 

Me
dic

ina
l p

ro
du

ct 
no

 lo
ng

er
 au

th
or

ise
d



24 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

A. LABELLING 

Me
dic

ina
l p

ro
du

ct 
no

 lo
ng

er
 au

th
or

ise
d



25 

 

PARTICULARS TO APPEAR ON THE OUTER PACKAGING 

 

OUTER CARTON 

 

 

1. NAME OF THE MEDICINAL PRODUCT 

 

Aerivio Spiromax 50 micrograms/500 micrograms inhalation powder 

salmeterol/fluticasone propionate 

 

 

2. STATEMENT OF ACTIVE SUBSTANCE(S) 

 

Each metered dose contains 50 micrograms of salmeterol (as salmeterol xinafoate) and 500 micrograms of 

fluticasone propionate. 

 

Each delivered dose (the dose from the mouthpiece) contains 45 micrograms of salmeterol (as salmeterol 

xinafoate) and 465 micrograms of fluticasone propionate. 

 

 

3. LIST OF EXCIPIENTS 

 

Contains lactose. See leaflet for further information 

 

 

4. PHARMACEUTICAL FORM AND CONTENTS 

 

Inhalation powder 

1 inhaler containing 60 doses. 

3 inhalers each containing 60 doses.  

 

 

5. METHOD AND ROUTE(S) OF ADMINISTRATION 

 
 

Read the package leaflet carefully before use. 

 
Inhalation use. 

 

 

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF 

THE SIGHT AND REACH OF CHILDREN 

 

Keep out of the sight and reach of children. 

 

 

7. OTHER SPECIAL WARNING(S), IF NECESSARY 

 

Use as directed by your doctor. 

 

Front panel: Not for use in children and adolescents. 

 

Side panel: For use in adults 18 years of age and older only. 

Me
dic

ina
l p

ro
du

ct 
no

 lo
ng

er
 au

th
or

ise
d



26 

 

Not for use in children or adolescents under 18 years of age. 

 

 

8. EXPIRY DATE 

 
EXP 

Use within 3 months of removing from foil wrapping. 

 

 

9. SPECIAL STORAGE CONDITIONS 

 

Do not store above 25°C. Keep the mouthpiece cover closed after the removal of foil wrap. 

 

 

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR 

WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE 

 

 

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER 

 

Teva B.V., Swensweg 5, 2031 GA Haarlem, Netherlands 

 

 

12. MARKETING AUTHORISATION NUMBER(S)  

 

EU/1/16/1122/001 

EU/1/16/1122/002 

 

 

13. BATCH NUMBER 

 

Lot  

 

 

14. GENERAL CLASSIFICATION FOR SUPPLY 

 

 

15. INSTRUCTIONS ON USE 

 

 

16. INFORMATION IN BRAILLE 

 

Aerivio Spiromax 50 mcg/500 mcg 

 

 

17. UNIQUE IDENTIFIER – 2D BARCODE 

 
<2D barcode carrying the unique identifier included.>] 

 

 

Me
dic

ina
l p

ro
du

ct 
no

 lo
ng

er
 au

th
or

ise
d



27 

18. UNIQUE IDENTIFIER – HUMAN READABLE DATA 

 

PC:  

SN:  

NN:  

 

 

Me
dic

ina
l p

ro
du

ct 
no

 lo
ng

er
 au

th
or

ise
d



28 

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS 

 

FOIL 

 

 

1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION 

 

Aerivio Spiromax 50 micrograms/500 micrograms inhalation powder 

 

salmeterol /fluticasone propionate 

 

Inhalation use 

 

 

2. METHOD OF ADMINISTRATION 

 

Read the package leaflet 

 

 

3. EXPIRY DATE 

 

EXP  

 

 

4. BATCH NUMBER 

 

Lot 

 

 

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 

 

Contains 1 inhaler 

 

 

6. OTHER 

 

Keep the mouthpiece cover closed and use within 3 months of removing from foil wrapping. 

 

Teva B.V.  

 

 

 

Me
dic

ina
l p

ro
du

ct 
no

 lo
ng

er
 au

th
or

ise
d



29 

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS 

 

INHALER 

 

 

1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION 

 

Aerivio Spiromax 50 micrograms/500 micrograms  

Inhalation powder 

 

salmeterol/fluticasone propionate 

 

Inhalation use 

 

 

2. METHOD OF ADMINISTRATION 

 

Read the package leaflet carefully before use. 

 

 

3. EXPIRY DATE 

 

EXP  

 

 

4. BATCH NUMBER 

 

Lot 

 

 

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 

 

60 doses 

 

 

6. OTHER 

 

Adults only. 

 

Contains lactose. 

 

Start: 

 

Teva B.V.  

 

 

 

 

 

 

 

 

 

 

Me
dic

ina
l p

ro
du

ct 
no

 lo
ng

er
 au

th
or

ise
d



30 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

B. PACKAGE LEAFLET 

Me
dic

ina
l p

ro
du

ct 
no

 lo
ng

er
 au

th
or

ise
d



31 

Package leaflet: Information for the patient 
 

Aerivio Spiromax 50 micrograms/500 micrograms inhalation powder 

salmeterol/fluticasone propionate 
 

Read all of this leaflet carefully before you start using this medicine because it contains important 

information for you. 
- Keep this leaflet. You may need to read it again.  
- If you have any further questions, ask your doctor, pharmacist or nurse. 
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if 

their signs of illness are the same as yours.  

- If you get any side effects, talk to your doctor pharmacist or nurse. This includes any possible side 

effects not listed in this leaflet. See section 4. 

 

What is in this leaflet 
 

1. What Aerivio Spiromax is and what it is used for  

2. What you need to know before you use Aerivio Spiromax  

3. How to use Aerivio Spiromax  

4. Possible side effects  

5. How to store Aerivio Spiromax 

6. Contents of the pack and other information 

 

 

1. What Aerivio Spiromax is and what it is used for 

 
Aerivio Spiromax contains two medicines, salmeterol and fluticasone propionate: 
 

 Salmeterol is a long-acting bronchodilator. Bronchodilators help the airways in the lungs to stay open. 
This makes it easier for air to get in and out. The effects last for at least 12 hours. 

 Fluticasone propionate is a corticosteroid which reduces swelling and irritation in the lungs. 
 

 

Your doctor has prescribed this medicine for the treatment of either 

 Severe asthma, to help prevent attacks of breathlessness and wheeziness,  
or 

 Chronic obstructive pulmonary disease (COPD), to reduce the number of flare ups of symptoms. 
 

You must use Aerivio Spiromax every day as directed by your doctor. This will make sure that it works 

properly in controlling your asthma or COPD. 

 

Aerivio Spiromax helps to stop breathlessness and wheeziness coming on. However, Aerivio Spiromax 

should not be used to relieve an attack of breathlessness or wheezing. If this happens you need to use a 

fast-acting ‘reliever’ (‘rescue’) inhaler, such as salbutamol. You should always have your fast-acting 

'rescue' inhaler with you. 

 

Aerivio Spiromax should only be used to treat severe asthma in adults aged 18 years and older and 

adults with COPD.  

 

2. What you need to know before you use Aerivio Spiromax  

 

Do not use Aerivio Spiromax: 
- if you are allergic (hypersensitive) to salmeterol, fluticasone propionate or any of the other ingredients 

of this medicine (listed in section 6). 

 

Warnings and precautions  

Me
dic

ina
l p

ro
du

ct 
no

 lo
ng

er
 au

th
or

ise
d



32 

Talk to your doctor, pharmacist or nurse before using Aerivio Spiromax if you have: 

 Heart disease, including an irregular or fast heart beat 

 Overactive thyroid gland 

 High blood pressure 

 Diabetes mellitus (Aerivio Spiromax may increase your blood sugar) 

 Low potassium in your blood  

 Tuberculosis (TB) now or have had in the past, or have other lung infections 
 

Contact your doctor if you experience blurred vision or other visual disturbances. 

 

Children and adolescents 

This medicine should not be used in children or adolescents under the age of 18 years. 

 

Other medicines and Aerivio Spiromax 
Tell your doctor or pharmacist if you are taking or, have recently taken or might use any other medicines. 

This includes other medicines for asthma or any medicines obtained without a prescription. Aerivio 

Spiromax may not be suitable to be taken with some other medicines.  

 

Tell your doctor if you are taking the following medicines, before starting to use Aerivio Spiromax: 

 Beta blockers (such as atenolol, propranolol and sotalol). Beta blockers are mostly used for high blood 
pressure or heart conditions such as angina. 

 Medicines to treat infections (such as ritonavir, ketoconazole, itraconazole and erythromycin). Some of 
these medicines may increase the amount of salmeterol or fluticasone propionate in your body. This can 

increase your risk of side effects with Aerivio Spiromax, including irregular heartbeats, or may make 

side effects worse. 

 Corticosteroids (by mouth or by injection). Recent use of these medicines might increase the risk of 
Aerivio Spiromax affecting your adrenal glands. 

 Diuretics, also known as ‘water tablets’ used to treat high blood pressure.  

 Other bronchodilators (such as salbutamol).  

 Xanthine medicines such as aminophylline and theophylline. These are often used to treat asthma. 
 

Some medicines may increase the effects of Aerivio Spiromax and your doctor may wish to monitor you 

carefully if you are taking these medicines (including some medicines for HIV: ritonavir, cobicistat). 

 

Pregnancy and breastfeeding  

If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist 

for advice before taking this medicine.  

 

It is not known whether this medicine can pass into breast milk. If you are breastfeeding, check with your 

doctor or pharmacist  for advice before taking this medicine. 

 

Driving and using machines 
Aerivio Spiromax is not likely to affect your ability to drive or use machines. 

 

Aerivio Spiromax contains lactose 

Lactose is a type of sugar found in milk. Lactose contains small amounts of milk protein which may cause 

allergic reactions. If you have been told by your doctor that you have an intolerance or allergy to lactose, 

other sugars, or milk, contact your doctor before taking this medicinal product. 

 

3. How to use Aerivio Spiromax 

 

Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or 

pharmacist if you are not sure. 

 Use your Aerivio Spiromax every day until your doctor advises you to stop. Do not take more than the 
recommended dose. Check with your doctor or pharmacist if you are not sure. 

Me
dic

ina
l p

ro
du

ct 
no

 lo
ng

er
 au

th
or

ise
d



33 

 Do not stop taking Aerivio Spiromax or reduce the dose of Aerivio Spiromax without talking to your 
doctor first. 

 Aerivio Spiromax should be inhaled through the mouth into the lungs. 
 

The recommended dose is: 

 

Severe asthma in adults 18 years of age and older 

 

One inhalation twice a day 

 

Chronic Obstructive Pulmonary Disease (COPD) 

 

One inhalation twice a day 

 

If you are using Aerivio Spiromax for asthma, your doctor will want to check your symptoms regularly. 

 

Your doctor will help you to manage your asthma and will adjust the dose of this medicine to the lowest dose 

that controls your asthma. If your doctor feels that you need a lower dose than is available from your Aerivio 

Spiromax, your doctor may prescribe an alternative inhaler containing the same active substances as your 

Aerivio Spiromax but with a lower dose of the corticosteroid. However, do not change the number of 

inhalations your doctor has prescribed without talking to your doctor first. 

 

If your asthma or breathing gets worse tell your doctor straight away. If you feel more wheezy, your 

chest feels tight more often or you need to use more of your fast-acting ‘reliever’ medicine, your chest 

condition may be getting worse and you could become seriously ill. You should continue to take Aerivio 

Spiromax but do not increase the number of puffs you take.  See your doctor at once as you may need 

additional treatment. 

 

Instructions for use 

 

Training 

Your doctor, nurse or pharmacist should provide you with training on how to use your inhaler, 

including how to take a dose effectively. This training is important to ensure you receive the dose you 

require. If you have not received this training please ask your doctor, nurse or pharmacist to show you 

how to use your inhaler properly before you use it for the first time.   

 

Your doctor, nurse or pharmacist should also check how you use your Spiromax device from time to time to 

ensure that you are using the device properly and as prescribed. If you are not using Aerivio Spiromax 

properly and/or you are not breathing in forcefully enough, this may mean that you are not getting enough of 

the medicine into your lungs.  If you are not getting enough medicine into your lungs, it will not help your 

asthma or COPD as it should 

 

Preparing your Aerivio Spiromax  

 

Before using your Aerivio Spiromax for the first time, you need to prepare it for use as follows: 

 Check the dose indicator to see that there are 60 inhalations in the inhaler. 

 Write the date you opened the foil pouch on the label on the inhaler. 

 You do not need to shake your inhaler before you use it. 
 

 

How to take an inhalation 

 

 

1. Hold your inhaler with the semi-transparent yellow mouthpiece cover at the bottom. You do not need to 
shake your inhaler. 

 

Me
dic

ina
l p

ro
du

ct 
no

 lo
ng

er
 au

th
or

ise
d



34 

 
 

 

2. Open the mouthpiece cover by folding it down until you hear one loud click. Your inhaler is now ready 
for use. 

 
  

3. Breathe out gently (as far as is comfortable). Do not breathe out through your inhaler. 
4. Place the mouthpiece between your teeth. Do not bite the mouthpiece. Close your lips around the 

mouthpiece. Take care not to block the air vents. 

 Breathe in through your mouth as deeply and as forcefully as you can.  

 Note that it is important that you breathe in forcefully. 

 

 

Me
dic

ina
l p

ro
du

ct 
no

 lo
ng

er
 au

th
or

ise
d



35 

  
 

5. Hold your breath for 10 seconds or as long as you comfortably can. 
 

6. Remove your inhaler from your mouth. You may notice a taste when you take your inhalation.  
 

 

 

 

 

 

 

 

 

 

 

 

 

 

7. Then breathe out gently (do not breathe out through the inhaler). Close the mouthpiece cover.  

 
 

 

Afterwards, rinse your mouth with water and spit it out and/or brush your teeth. This may help to stop you 

getting thrush in your mouth and/or becoming hoarse. 

Me
dic

ina
l p

ro
du

ct 
no

 lo
ng

er
 au

th
or

ise
d



36 

 

Do not try to take your inhaler apart, remove or twist the mouthpiece cover. The mouthpiece cover is fixed to 

your inhaler and must not be taken off. Do not use your inhaler if it is damaged or if the mouthpiece has 

come apart from your inhaler. Do not open and close the mouthpiece cover unless you are about to use your 

inhaler.  

 

If you open and close the mouthpiece without taking an inhalation the dose will be securely held inside the 

inhaler ready for the next inhalation. It is impossible to accidentally take extra medicine or a double dose in 

one inhalation. 

 

Keep the mouthpiece closed all the time unless you are about to use your inhaler. 

 

Cleaning your Inhaler 

Keep your inhaler dry and clean. 

If necessary you may wipe the mouthpiece of your inhaler after use with a dry cloth or tissue. 

 

When to start using a new Aerivio Spiromax 

 The dose indicator on the rear of the device tells you how many doses (inhalations) are left in your 
inhaler, starting with 60 inhalations when it is full.  

 

 
 

 The dose indicator shows the number of inhalations remaining in even numbers only. 

 For inhalations remaining from 20 downwards to ‘8’, ‘6’, ‘4’, ‘2’ the numbers are displayed in red on a 
white background. When the numbers become red in the window, you should see your doctor and get a 

new inhaler. 

 

 

Note:  

 The mouthpiece will still ‘click’ even when your inhaler is empty. If you open and close the 
mouthpiece without taking an inhalation the dose indicator will still register it as a count.  

 

If you use more Aerivio Spiromax than you should 
It is important to use the inhaler as instructed. If you accidentally take more doses than is recommended, talk 

to your doctor or pharmacist. You may notice your heart beating faster than usual and that you feel shaky. 

You may also have dizziness, a headache, muscle weakness and aching joints. 

 

If you have used too many doses of Aerivio Spiromax for a long time, you should talk to your doctor or 

pharmacist for advice. This is because using too much Aerivio Spiromax may reduce the amount of steroid 

hormones produced by your adrenal glands.  

 

If you forget to use Aerivio Spiromax 
Do not take a double dose to make up for a forgotten dose. Just take your next dose at the usual time. 

 

Me
dic

ina
l p

ro
du

ct 
no

 lo
ng

er
 au

th
or

ise
d



37 

If you stop using Aerivio Spiromax 

It is very important that you take your Aerivio Spiromax every day as directed. Keep taking it until your 

doctor tells you to stop. Do not stop or suddenly reduce your dose of Aerivio Spiromax. This could 

make your breathing worse. 

 

In addition, if you suddenly stop taking Aerivio Spiromax or reduce your dose of Aerivio Spiromax this may 

(very rarely) cause you to have problems with your adrenal glands (adrenal insufficiency) which sometimes 

causes side effects. 

 

These side effects may include any of the following: 

 

 Stomach pain 

 Tiredness and loss of appetite, feeling sick 

 Sickness and diarrhoea 

 Weight loss 

 Headache or drowsiness 

 Low levels of sugar in your blood 

 Low blood pressure and seizures (fits) 
When your body is under stress such as from fever, trauma (such as an accident or injury), infection, or 

surgery, adrenal insufficiency can get worse and you may have any of the side effects listed above. 

 

If you get any side effects, talk to your doctor or pharmacist. To prevent these symptoms, your doctor may 

prescribe extra corticosteroids in tablet form (such as prednisolone). 

 

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse. 

 

 

4. Possible side effects 
 

Like all medicines, this medicine can cause side effects, although not everybody gets them. To reduce the 

chance of side effects your doctor will prescribe the lowest dose of this combination of drugs to control your 

asthma or COPD. 

 

Allergic reactions: you may notice your breathing suddenly gets worse immediately after using Aerivio 

Spiromax. You may be very wheezy and cough or be short of breath. You may also notice itching, a rash 

(hives) and swelling (usually of the face, lips, tongue or throat), or you may suddenly feel that your heart is 

beating very fast or you feel faint and light headed (which may lead to collapse or loss of consciousness). If 

you get any of these effects or if they happen suddenly after using Aerivio Spiromax, stop using 

Aerivio Spiromax and tell your doctor straight away. Allergic reactions to Aerivio Spiromax are 

uncommon (they may affect up to 1 in 100 people).  

Other side effects are listed below: 

 

 

Very common (may affect more than 1 in 10 people) 

 Headache - this usually gets better as treatment continues. 

 Increased number of colds have been reported in patients with chronic obstructive pulmonary disease 
(COPD). 

 

Common (may affect up to 1 in 10 people) 

 Thrush (sore, creamy-yellow, raised patches) in the mouth and throat. Also sore tongue and hoarse voice 
and throat irritation. Rinsing your mouth out with water and spitting it out immediately and/or brushing 

your teeth after taking each dose of your medicine may help. Your doctor may prescribe an anti-fungal 

medicine to treat the thrush. 

 Aching, swollen joints and muscle pain. 

 Muscle cramps. 

Me
dic

ina
l p

ro
du

ct 
no

 lo
ng

er
 au

th
or

ise
d



38 

 

 

The following side effects have also been reported in patients with chronic obstructive pulmonary disease 

(COPD): 

 Pneumonia and bronchitis (lung infection). Tell your doctor if you notice any of the following symptoms 
while taking Aerivio Spiromax as they could be symptoms of a lung infection: fever or chills; increased 

mucus production, changes in mucus colour; increased cough or increased breathing difficulties. 

 Bruising and fractures. 

 Inflammation of sinuses (sinusitis, a feeling of tension or fullness in the nose, cheeks and behind the 
eyes, sometimes with a throbbing ache). 

 A reduction in the amount of potassium in the blood (you may get an uneven heartbeat, muscle 
weakness, cramp). 

 

Uncommon (may affect up to 1 in 100 people) 

 Increases in the amount of sugar (glucose) in your blood (hyperglycaemia). If you have diabetes, more 
frequent blood sugar monitoring and possibly adjustment of your usual diabetic treatment may be 

required. 

 Cataract (cloudy lens in the eye). 

 Very fast heart beat (tachycardia). 

 Feeling shaky (tremor) and fast or uneven heart beat (palpitations) - these are usually harmless and get 
less as treatment continues. 

 Chest pain. 

 Feeling worried (although this effect occurs mainly in children when prescribed this combination of 
drugs but in a lower strength). 

 Disturbed sleep. 

 Allergic skin rash. 
 

Rare (may affect up to 1 in 1,000 people) 

 Breathing difficulties or wheezing that gets worse straight after taking Aerivio Spiromax. If this 
happens stop using your Aerivio Spiromax inhaler. Use your fast acting ‘reliever’ inhaler to help your 

breathing and tell your doctor straight away. 

 Aerivio Spiromax may affect the normal production of steroid hormones in the body, particularly if you 
have taken high doses for long periods of time. The effects include: 

 Slowing of growth in children and adolescents 

 Thinning of the bones 

 Glaucoma 

 Weight gain 

 Rounded (moon shaped) face (Cushing’s syndrome) 
 

Your doctor will check you regularly for any of these side effects and make sure you are taking the 

lowest dose of this combination of drugs to control your asthma. 

 

 Behavioural changes, such as being unusually active and irritable (although these effects occur mainly in 
children when prescribed this combination of drugs but in a lower strength). 

 Uneven or irregular heart beat or an extra heart beat (arrhythmias). Tell your doctor, but do not stop 
taking Aerivio Spiromax unless the doctor tells you to stop. 

 A fungal infection in the oesophagus (food canal), which might cause difficulties in swallowing. 
 

 

Frequency not known, but may also occur: 

 Depression or aggression (although these effects are more likely to occur in children when prescribed 
this combination of drugs but in a lower strength). 

 Blurred vision 

 

Me
dic

ina
l p

ro
du

ct 
no

 lo
ng

er
 au

th
or

ise
d



39 

Reporting of side effects 

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects 

not listed in this leaflet. You can also report side effects directly via the national reporting system listed in 

Appendix V*. By reporting side effects you can help provide more information on the safety of this 

medicine. 

 

 

5. How to store Aerivio Spiromax 

 

 Keep this medicine out of the sight and reach of children. 

 Do not use this medicine after the expiry date which is stated on the carton and the label of your inhaler 
after EXP. The expiry date refers to the last day of that month. 

 Do not store above 25 oC. Keep the mouthpiece cover closed after removal of the foil wrapping. 

 Use within 3 months of removing from the foil wrapping. Use the label on the inhaler to write down 
the opening date of the foil pouch.  

 Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. 

 

 

6. Contents of the pack and other information 

 

What Aerivio Spiromax contains  

- The active substances are salmeterol and fluticasone propionate. Each metered dose contains 50 
micrograms salmeterol (as salmeterol xinafoate) and 500 micrograms fluticasone propionate. Each 

delivered dose (the dose that leaves the mouthpiece) contains 45 micrograms of salmeterol (as 

salmeterol xinafoate) and 465 micrograms of fluticasone propionate.  

- The other ingredient is lactose monohydrate (see section 2 under ‘Aerivio Spiromax contains lactose’).  
 

What Aerivio Spiromax looks like and contents of the pack 

Aerivio Spiromax is an inhalation powder.  

Each Aerivio Spiromax inhaler contains 60 inhalations and has a white body with a semi-transparent yellow 

mouthpiece cover. 

 

Packs of 1 and 3 inhalers. Not all pack sizes may be marketed in your country.  
 

Marketing Authorisation Holder  

 

Teva B.V. 

Swensweg 5, 2031 GA Haarlem, Netherlands 

 

 

 

Manufacturer 

 

Norton (Waterford) Limited T/A Teva Pharmaceuticals Ireland 

Unit 27/35, IDA Industrial Park, Cork Road, Waterford, Ireland 

 

Teva Pharmaceuticals Europe B.V., Swensweg 5, 2031 GA Haarlem, Netherlands 

 

(For Poland only) Teva Operations Poland Sp. z o.o. Mogilska 80 Str. 31-546 Kraków, Poland 
 

For any information about this medicine, please contact the local representative of the Marketing 

Authorisation Holder: 

  

België/Belgique/Belgien 

Teva Pharma Belgium N.V./S.A./AG  

Lietuva 

UAB “Sicor Biotech” 

Me
dic

ina
l p

ro
du

ct 
no

 lo
ng

er
 au

th
or

ise
d



40 

Tel/Tél: +32 3 820 73 73 

 

Tel: +370 5 266 02 03 

 

България 

Тева Фармасютикълс България ЕООД 

Teл: +359 2 489 95 82 

 

Luxembourg/Luxemburg 

Teva Pharma Belgium N.V./S.A./AG  

Tel/Tél: +32 3 820 73 73 

 

Česká republika 

Teva Pharmaceuticals CR, s.r.o.  

Tel: +420 251 007 111 

 

Magyarország 

Teva Gyógyszergyár Zrt  

Tel.: +36 1 288 64 00 

 

Danmark 

Teva Denmark A/S  

Tlf: +45 44 98 55 11 

 

 

Malta 

Teva Pharmaceuticals Ireland 

L-Irlanda 

Tel: +353 51 321 740 

 

Deutschland 

Teva GmbH 

Tel: +49 731 402 08 

 

Nederland 

Teva Nederland B.V. 

Tel: +31 800 0228 400 

 

Eesti 

Teva Eesti esindus UAB Sicor Biotech Eesti 

filiaal 

Tel: +372 661 0801 

Norge 

Teva Norway AS  

Tlf: +47 6677 55 90 

 

Ελλάδα 

Teva Ελλάς Α.Ε. 

Τηλ: +30 210 72 79 099 

 

Österreich 

ratiopharm Arzneimittel Vertriebs GmbH 

Tel: +43 1 97007 0 

 

 

España 

Teva Pharma S.L.U.  

Tél: +34 91 387 32 80 

 

Polska 

Teva Pharmaceuticals Polska Sp. z o.o. 

Tel.: +48 22 345 93 00 

France 

Teva Santé 

Tél: +33 1 55 91 7800 

Portugal  

Teva Pharma - Produtos Farmacêuticos Lda 

Tel: +351 21 476 75 50 

 

Hrvatska 

Pliva Hrvatska d.o.o 

Tel: + 385 1 37 20 000 

 

România 

Teva Pharmaceuticals S.R.L 

Tel: +4021 230 6524 

Ireland 

Teva Pharmaceuticals Ireland 

Tel: +353 51 321 740 

 

Slovenija 

Pliva Ljubljana d.o.o. 

Tel: +386 1 58 90 390 

 

Ísland 

Vistor 

Simi: +354 535 7000 

 

Slovenská republika 

Teva Pharmaceuticals Slovakia s.r.o. 

Tel: +421 2 5726 7911 

 

 

Italia 

Teva Italia S.r.l. 

Tel: +39 028 917 981 

 

 

 

Suomi/Finland 

Teva FinlandPuh/Tel: +358 20 180 5900 

 

Me
dic

ina
l p

ro
du

ct 
no

 lo
ng

er
 au

th
or

ise
d



41 

 

Κύπρος 

Teva Ελλάς Α.Ε. 

Ελλάδα 

Τηλ: +30 210 72 79 099 

 

Sverige 

Teva Sweden AB 

Tel: +46 42 12 11 00 

 

Latvija 

Sicor Biotech filiāle Latvijā  

Tel: +371 67 323 666 

 

United Kingdom 

Teva UK Limited 

Tel: +44 1977 628 500 

 

 

This leaflet was last revised in month YYYY. 

 

Other sources of information 

 

Detailed information on this medicine is available on the European Medicines Agency web site: 

http://www.ema.europa.eu 

 

Me
dic

ina
l p

ro
du

ct 
no

 lo
ng

er
 au

th
or

ise
d


	SUMMARY OF PRODUCT CHARACTERISTICS
	A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE
	B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE
	C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
	D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
	A. LABELLING
	B. PACKAGE LEAFLET